<DOC>
	<DOC>NCT00813358</DOC>
	<brief_summary>The Zenith TX2® Post-market Approval Study is a clinical trial approved by US FDA to further study the safety and effectiveness of the Zenith TX2® TAA Endovascular Graft in the treatment of thoracic aortic aneurysms.</brief_summary>
	<brief_title>Zenith TX2® Post-market Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
	<criteria>Descending thoracic aortic aneurysm with diameter greater than or equal to 5.0 cm; or Descending thoracic aortic aneurysm with a history of growth greater than or equal to 0.5 cm within the previous 12 months; or Descending thoracic aortic degenerative or atherosclerotic ulcers greater than or equal to 10 mm in depth and 20 mm in diameter Age less than 18 years Other medical condition that may cause the patient to be noncompliant with the protocol, confound the results, or is associated with limited life expectancy (i.e., less than 2 years) Pregnant, breastfeeding, or planning on becoming pregnant within 24 months Unwilling or unable to comply with the followup schedule Inability or refusal to give informed consent Simultaneously participating in another investigative device or drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Endovascular Aneurysm Repair</keyword>
	<keyword>Aortic Aneurysm</keyword>
	<keyword>Thoracic</keyword>
</DOC>